A randomized‐controlled trial to evaluate the app‐based multimodal weight loss program zanadio for patients with obesity
Authors' conclusion
This study showed that adults with obesity who have used zanadio achieved a significant and clinically relevant weight loss within 12 months and improved further obesity-related health variables compared with a control group. Because of its effectiveness and flexible applicability, the app-based multimodal treatment zanadio might alleviate the present care gap for patients with obesity in Germany.
Study context
- Population
- Adults with obesityrandomized
- Participants
- 150 adults
- Comparison
- App-based multimodal weight loss program zanadio vs wait list control
- Primary endpoint
- Weight change (% of initial weight)
- Follow-up
- 12 months
Methodological detailsConducted January 2021 to March 2022; end points assessed every 3 months for up to 1 year via telephone interviews and online questionnaires
- Conducted January 2021 to March 2022; end points assessed every 3 months for up to 1 year via telephone interviews and online questionnaires
Primary result
As reported in the abstract
Intervention
−7.75
mean · 95% CI −9.66%–-5.84% · %
Wait list control
0.00
mean · 95% CI −1.98%–1.99% · %
Secondary outcomes
Quality of life, well-being, waist to height ratio · 12 months
- All secondary end points improved significantly in the intervention group
- Significantly greater improvements in well-being and waist to height ratio vs control
Original publication
A randomized‐controlled trial to evaluate the app‐based multimodal weight loss program zanadio for patients with obesity. Obesity (Silver Spring). Published 26 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →